Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells

PLoS Pathogens

Volumn 6, Issue 11, 2010, Pages

  Natesampillai, Sekar ^a   Nie, Zilin ^b   Cummins, Nathan W ^a   Jochmans, Dirk ^c   Bren, Gary D ^a   Angel, Jonathan B ^d   Badley, Andrew D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Tibotec BVBA   (Benin)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROCASPASE 8; CASPASE 8; MESSENGER RNA;

ADULT; ANTIVIRAL THERAPY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DEATH; CELL KILLING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MALE; POINT MUTATION; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; WILD TYPE; ANTIVIRAL RESISTANCE; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MUTATION; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VIROLOGY; WESTERN BLOTTING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; CASPASE 8; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; VIRUS REPLICATION; YOUNG ADULT;

EID: 79251523843     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001213     Document Type: Article

References (44)

1. Collazos J, Asensi V, Carton JA (2009) CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors. AIDS Res Hum Retroviruses 25: 647-655.
2. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401-410.
3. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52-59.
4. Pitrak DL, Bolanos J, Hershow R, Novak RM (2001) Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. Aids 15: 1317-1319.
5. Solomon A, Lane N, Wightman F, Gorry PR, Lewin SR (2005) Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drug-resistant virus and declining CD4+ T-cell counts. J Acquir Immune Defic Syndr 40: 140-148.
6. Lecossier D, Bouchonnet F, Schneider P, Clavel F, Hance AJ (2001) Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 183: 1009-1016.
7. D'Ettorre G, Forcina G, Andreotti M, Sarmati L, Palmisano L, et al. (2002) Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. Aids 16: 1877-1885.
8. Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, et al. (2003) Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol 77: 6041-6049.
9. Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, et al. (2003) Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitorbased highly active antiretroviral therapy: immune response and viral control. J Infect Dis 187: 1027-1037.
10. Kaplan SS, Ferrari G, Wrin T, Hellmann NS, Tomaras GD, et al. (2005) Longitudinal assessment of immune response and viral characteristics in HIVinfected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses 21: 13-16.
11. Schechter M, Tuboi SH (2006) Discordant immunological and virological responses to antiretroviral therapy. J Antimicrob Chemother 58: 506-510.
12. van Griensven J, Zachariah R, Rasschaert F, Reid T (2009) Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr 50: 556-558.
13. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344: 472-480.
14. Varbanov M, Espert L, Biard-Piechaczyk M (2006) Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Rev 8: 221-236.
15. Kaplan AH, Swanstrom R (1991) Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A 88: 4528-4532.
16. Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, et al. (2002) HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 9: 1172-1184.
17. Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, et al. (2007) Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol 81: 6947-6956.
18. Algeciras-Schimnich A, Belzacq-Casagrande A, Bren GD, Nie Z, Taylor JA, et al. (2007) Analysis of HIV protease killing through Caspase 8 reveals a novel interaction between caspase 8 and mitochondria. The Open Virology Journal 1: 39-46.
19. Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, et al. (2010) Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis 202: 386-391.
20. Nie Z, Bren GD, Rizza SA, Badley AD (2008) HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells. Open Virol J 2: 1-7.
21. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, et al. (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. Aids 13: 2349-2359.
22. Hawley-Foss N, Mbisa G, Lum JJ, Pilon AA, Angel JB, et al. (2001) Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis 33: 344-348.
23. Meroni L, Varchetta S, Manganaro D, Gatti N, Riva A, et al. (2002) Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virusinfected patients with discordant response to protease inhibitors. J Infect Dis 186: 143-144.
24. Rose JR, Babe LM, Craik CS (1995) Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol 69: 2751-2758.
25. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, et al. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
26. Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, et al. (2006) The independent effect of drug resistance on T cell activation in HIV infection. Aids 20: 691-699.
27. Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, et al. (2001) Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses 17: 517-523.
28. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, et al. (2001) Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 7: 712-718.
29. Lucas GM (2005) Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 55: 413-416.
30. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT (1999) Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73: 3744-3752.
31. Manosuthi W, Butler DM, Perez-Santiago J, Poon AF, Pillai SK, et al. Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. Aids 24: 411-416.
32. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
33. Harper ME, Marselle LM, Gallo RC, Wong-Staal F (1986) Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A 83: 772-776.
34. Costigliola P, Tumietto F, Ricchi E, Chiodo F (1992) Detection of circulating p24 antigen-positive CD4+ cells during HIV infection by flow cytometry. Aids 6: 1121-1125.
35. Marechal V, Clavel F, Heard JM, Schwartz O (1998) Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 72: 2208-2212.
36. Rigg RJ, Dando JS, Escaich S, Plavec I, Bohnlein E (1995) Detection of intracellular HIV-1 Rev protein by flow cytometry. J Immunol Methods 188: 187-195.
37. Brockman MA, Tanzi GO, Walker BD, Allen TM (2006) Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J Virol Methods 131: 134-142.
38. Zhou Y, Zhang H, Siliciano JD, Siliciano RF (2005) Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79: 2199-2210.
39. Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell Jt, Bixby D, et al. (2010) HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 16: 446-451.
40. Gange SJ, Schneider MF, Grant RM, Liegler T, French A, et al. (2006) Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr 41: 68-74.
41. Izopet J, Marchou B, Charreau I, Saune K, Tangre P, et al. (2008) HIV-1- resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response. Antivir Ther 13: 537-545.
42. Rodes B, Garcia F, Gutierrez C, Martinez-Picado J, Aguilera A, et al. (2005) Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol 77: 23-28.
43. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, et al. (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42: 269-276.
44. Jayaraman S (2005) Flow cytometric determination of mitochondrial membrane potential changes during apoptosis of T lymphocytic and pancreatic beta cell lines: comparison of tetramethylrhodamineethylester (TMRE), chloromethyl-Xrosamine (H2-CMX-Ros) and MitoTracker Red 580 (MTR580). J Immunol Methods 306: 68-79.